Neomorphic ERα Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery.
Abstract
In this issue of Cancer Cell, Jeselsohn et al. dissect the function of several of
the most clinically important estrogen receptor alpha mutants associated with endocrine
therapy resistance in breast cancer and demonstrate that they manifest disease-relevant
neomorphic activities that likely contribute to tumor pathogenesis.
Type
Journal articlePermalink
https://hdl.handle.net/10161/16118Published Version (Please cite this version)
10.1016/j.ccell.2018.01.014Publication Info
(2018). Neomorphic ERα Mutations Drive Progression in Breast Cancer and Present a Challenge
for New Drug Discovery. Cancer Cell, 33(2). pp. 153-155. 10.1016/j.ccell.2018.01.014. Retrieved from https://hdl.handle.net/10161/16118.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Ching-yi Chang
Associate Research Professor of Pharmacology and Cancer Biology
The main focus of my research has been to define the roles of nuclear hormone receptors
(NHRs) in the pathogenesis of disease, with a focus on hormone-related cancers.
During earlier stages of my research career, definition of the structural and molecular
determinants of NHR receptor biology and pharmacology was the main focus. Information
obtained from these studies was used to guide the development of receptor modulators
for therapeutic interventions and to gain insights
Donald Patrick McDonnell
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School
of Medicine
Lab WebsiteThe research in our group is focused on the development and application
of mechanism based approaches to identify novel therapeutics for use in the treatment
and prevention of hormonally responsive cancers. Specifically we are interested in
the pharmaceutical exploitation of the estrogen and androgen receptors as therapeutic
targets in breast and prostate cancers and in defining how these receptors influence
the pathoge
John David Norris
Associate Research Professor in Pharmacology & Cancer Biology
Molecular pharmacology of the nucler receptor class of transcription factors. Special
interest in the mode of action of tissue specific ligands for the estrogen and androgen
receptors.
Alphabetical list of authors with Scholars@Duke profiles.
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info